For the Inventor, By the Inventor

Enter assignee name

Valbonne, France

Nicox S.a.

USPTO Granted Patents = 110

% Expired Patents = 60.9

CIPO Patents = 12

EPO Patents = 29

Trademarks = 2

Forward Citations = 613

Loading Chart...

Loading Chart...

92 inventors (with patents filed for the assignee):

Piero Del Soldato (61 out of 65 patents)

Francesca Benedini (27 out of 34 patents)

Ennio Ongini (25 out of 32 patents)

4. Nicoletta Almirante (15 out of 27 patents)

5. David S Garvey (9 out of 101 patents)

6. Valerio Chiroli (9 out of 9 patents)

7. Laura Storoni (7 out of 15 patents)

8. Francesco Impagnatiello (7 out of 7 patents)

9. L Gordon Letts (7 out of 44 patents)

10. Cheri A Stevenson (6 out of 31 patents)

11. Stefano Biondi (6 out of 13 patents)

12. Elena Bastia (6 out of 9 patents)

13. Richard A Earl (6 out of 17 patents)

14. Maiko Ezawa (6 out of 13 patents)

15. Xinqin Fang (6 out of 18 patents)

Core Competencies:

Nitric Oxide

Prostaglandins

Ophthalmology

Phosphodiesterase

Glaucoma

Vaso Occlusive

Chronic Pain

Steroidal Compounds

NSAIDs

Drug Delivery

Cardiovascular Agents

Nitrooxyderivatives

110 patents: Sort by Forward Citations

1. 12728131 - Compositions for the treatment of glaucoma and ocular hypertension (2026-09-08),

2. 12709597 - PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE (2026-08-18),

3. 12642800 - Nitric oxide releasing phosphodiesterase type 5 inhibitor (2026-06-02),

4. 12642783 - Method for treating vaso occlusive crises associated with Sickle cell disease (2026-06-02),

5. 12186295 - Ophthalmic compositions containing a nitric oxide releasing prostamide (2025-01-07),

6. 12178793 - Ophthalmic compositions containing a nitric oxide releasing prostamide (2024-12-31),

7. 11980618 - Nitric oxide releasing phosphodiesterase type 5 inhibitor (2024-05-14),

8. 11660282 - Method for treating vaso occlusive crises associated with sickle cell disease (2023-05-30),

9. 11058691 - Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma (2021-07-13),

10. 11020368 - Ophthalmic compositions containing a nitric oxide releasing prostamide (2021-06-01),

11. 10988438 - Process for the preparation of a nitric oxide donating prostaglandin analogue (2021-04-27),

12. 10688073 - Ophthalmic compositions containing a nitric oxide releasing prostamide (2020-06-23),

13. 10610509 - Combinations of prostaglandins and nitric oxide donors (2020-04-07),

14. 10280138 - Nitric oxide donating derivatives of fluprostenol (2019-05-07),

15. 10220055 - Composition effective against viral conjunctivitis (2019-03-05),

Nicox S.a., headquartered in Valbonne, France, is a biopharmaceutical company specializing in the development of innovative ophthalmic compositions. The company focuses on leveraging core technologies related to nitric oxide, prostaglandins, and phosphodiesterase to address various ocular conditions, including glaucoma and chronic pain. Nicox is dedicated to advancing therapeutic solutions that enhance patient care in the field of ophthalmology, emphasizing the importance of targeted treatments for eye health.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

110 Patents

#1 in Valbonne

#254 in France

#7,151 in the World

Valbonne, France

Nicox S.a.

Forward Citations = 613

92 inventors:

Piero Del Soldato (61 out of 65 patents)

Francesca Benedini (27 out of 34 patents)

Ennio Ongini (25 out of 32 patents)

4. Nicoletta Almirante (15 out of 27 patents)

5. David S Garvey (9 out of 101 patents)

Please report any incorrect information to [email protected]

Loading…